Aethlon Medical (NASDAQ:AEMD) Raised to Sell at Wall Street Zen

Aethlon Medical (NASDAQ:AEMD) was upgraded by Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aethlon Medical has an average rating of “Reduce”.

Aethlon Medical Stock Performance

Shares of Aethlon Medical stock opened at $3.15 on Friday. The stock has a market cap of $2.05 million, a price-to-earnings ratio of -0.21 and a beta of 1.41. The stock has a 50 day moving average price of $5.60 and a 200-day moving average price of $9.15. Aethlon Medical has a one year low of $2.63 and a one year high of $137.00.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. 1.99% of the stock is currently owned by hedge funds and other institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.